Kratom Alkaloid Mitragynine Disrupts Nerve Cell Proteins in Tolerance-Consistent Pattern, Proteomics Study Finds

Why it matters

This is the first proteomics-level analysis of how mitragynine -- kratom's principal alkaloid -- alters protein expression in peripheral nerve-supporting Schwann cells. The findings identify molecular pathways consistent with tolerance development and potential neurotoxic risk from prolonged use, providing cellular-level evidence directly relevant to current regulatory debates over kratom safety.

The big picture

As the DEA moves to schedule 7-OH and kratom use grows as an opioid substitute, basic science on kratom's cellular mechanisms has lagged behind policy. Most prior kratom research focused on receptor binding and behavioral outcomes in animals. This Chulalongkorn University study is among the first to map downstream proteomic consequences of mitragynine exposure in human-relevant cell types, adding molecular detail that previous studies could not provide. It was funded by the Second Century Fund and Thailand Science Research and Innovation (TSRI), with no declared competing interests.

Key findings

• Researchers exposed RSC96 Schwann cells to 20 µM mitragynine (the highest non-cytotoxic concentration) for 72 hours and used LC-MS/MS mass spectrometry proteomics
• 91 proteins showed significant expression changes: 60 downregulated and 31 upregulated
• Downregulated proteins were concentrated in translational machinery, cytoskeletal organization, and metabolic pathways essential to Schwann cell homeostasis
• AMP-activated protein kinase (AMPK) emerged as a high-centrality hub node within the disrupted protein interaction network
• Upregulated proteins were enriched in xenobiotic stress responses, aminoacyl-tRNA biosynthesis, and chromatin remodeling pathways
• Structural similarity analysis showed limited overlap between mitragynine and morphine despite their shared mu-opioid receptor target

What they say

The authors conclude that 'chronic mitragynine exposure induces coordinated proteomic and network-level remodeling in Schwann cells, identifying regulatory pathways consistent with tolerance-related cellular adaptation and peripheral neurotoxic risk.' (Authors, Chulalongkorn University / Archives of Toxicology, Springer Nature, 2026; DOI: 10.1007/s00204-026-04461-5)

Bottom line

A new proteomics study finds mitragynine significantly disrupts nerve-supporting cell proteins in patterns consistent with tolerance and peripheral neurotoxic risk -- the kind of cellular-level mechanistic evidence regulators and clinicians need as kratom scheduling decisions accelerate in 2026.